---
title: "Garden Biopharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 309 million yuan, a year-on-year increase of 60.76%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/232955111.md"
description: "Garden Biopharmaceutical released its 2024 annual report, with operating revenue of 1.243 billion yuan, a year-on-year increase of 13.58%; net profit attributable to shareholders of 309 million yuan, a year-on-year increase of 60.76%; earnings per share of 0.57 yuan, and plans to distribute a cash dividend of 1.14 yuan for every 10 shares. The company has improved its profitability through operational optimization and process improvements, and actively participated in national centralized procurement, with multiple products selected"
datetime: "2025-03-24T11:28:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/232955111.md)
  - [en](https://longbridge.com/en/news/232955111.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/232955111.md)
generator: "portal-rs"
---

# Garden Biopharmaceutical released its 2024 annual performance, with a net profit attributable to the parent company of 309 million yuan, a year-on-year increase of 60.76%

According to the Zhitong Finance APP, Garden Biopharmaceutical (300401.SZ) released its 2024 annual report, stating that the company's annual revenue for 2024 is CNY 1.243 billion, a year-on-year increase of 13.58%; the net profit attributable to shareholders of the listed company is CNY 309 million, a year-on-year increase of 60.76%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is CNY 257 million, a year-on-year increase of 74.02%; the basic earnings per share is CNY 0.57. It is proposed to distribute a cash dividend of CNY 1.14 (including tax) for every 10 shares to all shareholders.

During the reporting period, facing a complex and changing external environment, the company closely monitored market dynamics, optimized its business operation model, and enhanced its profitability. At the same time, the company continuously reduced costs and improved product competitiveness through ongoing process improvements and energy-saving measures. During the reporting period, as the national procurement execution time for products such as Valsartan Amlodipine Tablets, Theophylline Injection, Levofloxacin Tablets, and Alpha-Lipoic Acid Injection expired, Garden Pharmaceuticals actively participated in the follow-up bidding organized by various provinces. Valsartan Amlodipine Tablets were selected in 26 provinces; Theophylline Injection was selected in 23 provinces; Levofloxacin Tablets and Alpha-Lipoic Acid Injection were selected in the Jiangsu Alliance procurement; Escitalopram Oxalate Tablets were selected in 20 provinces

### Related Stocks

- [300401.CN](https://longbridge.com/en/quote/300401.CN.md)

## Related News & Research

- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [FOCUS-Green giant: How Taylor Farms became a top salad supplier before US diarrhea outbreak](https://longbridge.com/en/news/296469939.md)
- [Unipar Carbocloro: Strong financials, capacity expansion, and ESG leadership drive resilient growth](https://longbridge.com/en/news/296149106.md)
- [VNET Announces Strategic Cooperation with CATL | VNET Stock News](https://longbridge.com/en/news/296212256.md)
- [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**